Objectives: Elderly patients seem vulnerable to digoxin toxicity because of their diminished organ functions and tendency to encounter drug interactions. The aim of this research was to explore the extent of the concurrent use of digoxin with Chinese medications (CMs), its contributing factors, and the relevant consequences. Methods: A retrospective population-based cohort study was conducted using Longitudinal Health Insurance databases in Taiwan. Those elderly patients being prescribed with digoxin in outpatient settings in 2006 were evaluated for the incidence, prevalence, and duration of concurrent use with concentrated CMs in 2006. After 1:1 random matching to select the corresponding digoxin-only elderly users, univariate and multivariate logistic regression analyses were performed to explore factors associated with concomitant incident digoxin-CM use and incident digoxin-specific CM use. The relevant clinical and economic outcomes for a 3-month follow-up period from the initial exposure of incident digoxin-CM use were compared. Results: Of 185,076 elderly, 6,374 were prescribed with digoxin and 789 were CM-digoxin users in 2006. The prevalence and incidence of concomitant CM use among digoxin elderly users were 0.43% and 0.22%, respectively. Although the other factors were not statistically significantly associated with incident CM-digoxin use, patients with heart diseases and with benign prostate hypertrophy had an increased likelihood of incident CM-digoxin use of 115% and 102%, respectively. Almost all the concerned clinical and economic outcomes were not statistically significantly different between incident exposure or not, except for the use of potassium-sparing and nonsteroidal antiinflammatory drugs. Conclusions: There was a relatively low incidence of digoxin-CM use among the elderly in Taiwan. Although no significant effects on clinical and economic outcomes occurred, it is necessary to monitor potential side effects of digoxin more aggressively for those vulnerable elderly using digoxin with CMs, especially for those who tended to expose to incident digoxin-CM use elderly patients.
Introduction
Elderly people, especially those with chronic conditions, are more prone to experiencing drug interactions and adverse drug reactions because they often take many medications together and have diminished body functions, along with multiple chronic illnesses [1, 2] . A systematic review reported that 1% to 61% of the patients, including the elderly, with cardiovascular diseases used complementary and alternative medicine (CAM), whereas 2% to 46% of them used herbal medicine [3] . In particular, 53% to 60% of CAM users, in which older adults accounted for the majority, tended not to disclose their use to primary health care providers [4, 5] . Less than half of nurses, physicians, and pharmacists documented the patients' use of natural health products in their medical records [6] . Therefore, the World Health Organization has recommended the supervision of Western medicine practices together with traditional, complementary, and alternative medicines [7] . For those frail elderly, the use of herbal medicine with regular use of Western medications, especially those with narrow therapeutic indexes, might pose potential safety concerns to individuals that could be mitigated by health professionals to some extent.
Digoxin, one of the positive inotropic agents, is used for many conditions, including heart failure (HF) and atrial fibrillation, both of which are very common chronic diseases among elderly patients [8] . Digoxin has a narrow therapeutic index and tends to have drug interactions with other Western and Chinese medications (CMs) due to pharmacokinetic mechanisms (e.g., altered renal P-glycoprotein-mediated transport), pharmacodynamic mechanisms (e.g., result in hypopotassemia), and its life-threatening toxicities [9] . The dose of digoxin more than 0.125 mg per day is considered potentially inappropriate for older adults based upon the update, Beers Criteria [10] . In addition, it might be necessary to concern the increasing digoxin toxicity due to the occurrences of potential interactions between digoxin and clarithromycin [11] , and with some herbal medicines (e.g., chan su, lu-shen-wan, dan shen, asian ginseng, siberian ginseng, and shan zha) [12] [13] [14] .
Herbal medications such as digitalis, however, have been used to treat ailments since ancient times [15] . People believe that herbal medications do not cause any problems and are safe to use, even if the active ingredients of many herbs may interact with synthetic medications and result in the occurrence of adverse drug reactions [16] [17] [18] . For instance, elderly patients with HF seem liable to use herbal medicines to receive their benefits [19] . Although the concurrent use of herbal medications may show synergistic, agonistic, or antagonistic effects on Western medications, those aforementioned studies showed the existence of significant interactions between digoxin and CMs on pharmacokinetic and pharmacodynamic aspects. To date, information on the actual exposure of digoxin with CMs among older adults and its contributing factors is limited, as is information about its good or bad effects on patients.
For the past decade, the use of CAM, including Traditional Chinese Medicine (TCM), has been rising globally [20, 21] , as well as in Taiwan [22] . An Australian study conducted in 2007 showed that Chinese medicine usage accounted for 20% of all CAM use among older Australian women [23] . There were 10%, 28%, and 63% of National Health Insurance (NHI) beneficiaries who had reported using TCM services in Taiwan in periods of 1 month, 1 year, and 6 years, respectively [24] . In particular, concentrated CMs, which are the extracts of single CMs, and combined CM remedy products are the most commonly used TCM therapies in Taiwan. The use of concentrated CM has increased [25] . These concentrated CMs are those medications derived from the TCM theories so that the active chemical ingredients of concentrated CM products are the same as the crude CM products, except the starches as the excipients in the concentrated CM products. Almost all concentrated CMs have been covered by Taiwan's NHI since the NHI program's inception in 1995. The quality of concentrated CMs is important, and its processing should comply with the current good manufacture practice to control the authorization and licensing for manufacture and sale of concentrated CM products in Taiwan [26] . Detailed registered information about the individual CM component, quantity, TCM indication, TCM efficacy, and manufacturing of the concentrated CMs is provided transparently on the Web site of the Department of Chinese Medicine and Pharmacy, Ministry of Health and Welfare, using traditional Chinese language [27] . Regarding the use of appropriate medication and its corresponding clinical effects among vulnerable older adults, especially for those who took Western medications with a narrow therapeutic index, the aim of this study was to explore the extent of the concurrent use of digoxin with concentrated CMs, its contributing factors, and the relevant consequences for the elderly.
Methods

Study Design
This population-based retrospective cohort study was conducted to 1) examine the prevalence and incidence of concurrent use and interactions of digoxin with concentrated CMs among elderly NHI beneficiaries, and describe their use patterns; 2) explore the contributing factors associated with incident digoxin-CM use and incident digoxin-specific CM interactions; and 3) examine the relevant effects of incident digoxin-specific CM interactions.
Data Sources
This study used the 2 million sampling claimed data, National Health Research Insurance Database (NHIRD), which represents the entire insured Taiwanese population (i.e., 23 million individuals).
More specifically, we used the Longitudinal Health Insurance  Database 2000 and 2005 (LHID 2000 and LHID 2005) for the analyses. This is one of the formal population databases containing information about prescription data of Western medications and concentrated CMs under the national insurance program. This study was exempt from the institutional review board because the NHIRD database contains de-identified person data and de-identified health care settings. The NHIRD is publicly available only through the proper application process for researchers.
Study Population
We focused on elderly digoxin users because elderly patients are more likely to be given medication inappropriately, encounter adverse drug reactions (i.e., electrolyte imbalance, gastrointestinal upset), and/or experience drug interactions due to the use of digoxin and other medications together [2, 10] . The prevalence and incidence of the concurrent use of digoxin with CMs in 2005 for all ages of the NHI population in Taiwan were 10.7% and 5.4%, respectively [14] . Thus, we extended these findings to conduct this study and further identified those elderly NHI beneficiaries who survived and were prescribed digoxin in 2006. By analyzing outpatient records, those elderly who were prescribed CMs with digoxin for at least 1 day were identified as digoxin-CM elderly users, whereas the incident digoxin-CM elderly users were those digoxin-CM elderly individuals who had no prescription records about previous CM use for the 6-month period before the date of first CM prescription use in 2006.
Furthermore, we evaluated the occurrence and consequences of interactions between digoxin and other prespecified CM products, that is, da huang, hawthorn, dan shen, licorice, oyster shell, siberian ginseng, senna, and aloe vera, which were obtained from one of the research team's systematic review study, for which partial results were published recently [28] . The incidence of digoxin-specific CM interactions among the incident digoxin-CM elderly users was estimated. Furthermore, we used Greedy algorithms to match and select one counterpart of digoxin-only users for each incident digoxin-CM elderly user and incident digoxin-specific CM elderly user on the basis of corresponding propensity scores derived from the combination of the following variables to reduce the selection bias: the month of the index date, the same duration of digoxin use, age, with or without catastrophic illness certification, outpatient clinic visits per year, number of prescribed distinct medications, and total medical expenditure. Thus, the index date of the selected digoxin-only elderly user was the same as that of the corresponding incident digoxin-CM elderly user.
Potential Factors Associated with Incident Digoxin-CM Use and Occurrence of Interactions among the Elderly
Those listed factors relevant to incident concurrent use of highrisk Western medications and CMs or CAM in previous studies [4, 14, 25, 29] were considered potential factors that were associated with incident digoxin-CM use and incident digoxin-specific CM interactions. In particular, those patients' information about their comorbidities (based on the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM] codes) and health service utilizations (i.e., outpatient clinic visits, number of prescribed distinct medications, ever hospitalization, total medical expenditure) was ascertained during the 6-month period before the dates of first CM prescription, in terms of index dates.
The number of prescribed distinct medications infers all items of distinct medications prescribed by either Western medicine physicians and/or Chinese medicine physicians during the 6-month period before the index dates reported in the NHIRD records. [NSAIDs] , and medication that might cause transcellular potassium shift) [9] .
Statistical Analyses
The corresponding findings were presented as mean Ϯ SD, or frequency (relative frequency, %). Differences between groups of patients on continuous variables were analyzed using independent t tests, and differences on nominal-scale variables were analyzed using Pearson's chi-square test. To explore the factors associated with the new concurrent use of digoxin and CMs and the incident occurrence of digoxin-specific CM interactions among the elderly, patient characteristics and health service utilizations were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to estimate the crude odds ratios, adjusted ORs, and 95% confidence interval to quantify the risk of incident digoxin-CM use and incident digoxin-specific CM interactions. All the potential factors listed were included in the model for multivariate analyses, and all analyses were performed using SAS version 9.2 (SAS Institute, Inc., Cary, NC).
Results
Of the 2 million randomly selected NHI beneficiaries, 9.25% were considered elderly in 2005 and survived to 2006. There were 6373 elderly individuals prescribed with digoxin (prevalence of digoxin prescription in elderly ¼ 3.4%) (Fig. 1) , and the average duration of digoxin prescription was 190.41 Ϯ 137.02 days (maximum ¼ 365 days) in 2006. In total, 789 patients were prescribed with concentrated CMs for at least 1 day (prevalence of digoxin-CM use among the elderly ¼ 0.43%). The incidence of digoxin-CM use among the elderly was 0.22% (N ¼ 400). The average duration of concurrent use was 17.25 Ϯ 23.89 days (maximum ¼ 228 days) in 2006. Of the 400 incident digoxin-CM elderly users, 385 (96.5%) had ever encountered evidence-approved digoxin-specific CM interactions. The most common occurrence of digoxin-specific CM interaction was digoxin-licorice (94% of all incident digoxin-CM elderly users and 98% of all incident digoxin-specific CM elderly users), and the average duration of concurrent use was 16.52 Ϯ 23.65 days in 2006 (Table 1) .
Although the 1:1 matching approach using specified propensity score was performed, there were some different characteristics between incident digoxin-CM elderly users and digoxinonly elderly users, in terms of mean age, presence of heart diseases or benign prostatic hyperplasia (BPH), number of outpatient clinic visits per month, and number of prescribed distinct medications (Table 2 ). This implies that incident digoxin-CM elderly users had a higher prevalence of heart diseases and BPH than did digoxin-only elderly users. The other potential factors were the same between these two groups of elderly patients, in terms of not reaching statistical significance.
The univariate and multivariate logistic regression analyses also indicated that crude ORs and adjusted ORs for those patients with diagnoses of heart diseases and BPH were statistically significantly different between incident digoxin-CM elderly users and digoxin-only users, as well as significantly different between those digoxin elderly users who encountered interactions with prespecified CMs and their counterpart digoxin-only users (Table 3) . Although the other factors were not statistically significantly associated with incident CM-digoxin use, patients with heart diseases and BPH had an increased likelihood of incident CM-digoxin use of 115% and 102%, respectively. Definitely, those elderly who made two to five outpatient visits per month and who had ever been prescribed more distinct medications tended to newly use digoxin with CMs. Those elderly NHI beneficiaries enrolled in the south region were approximately 38% less likely to encounter incident digoxin-CM concurrent use.
Of those elderly whom we evaluated for their outcomes (N ¼ 692), after 3-month follow-up from the index dates of digoxinspecific CM use and the counterpart digoxin-only use, there was a higher occurrence of all-cause hospitalizations, more diagnoses with hypopotassemia, more checks of digoxin levels, more concurrent prescriptions of potassium-sparing medications and NSAIDs, and higher mean total medical expenditure on emergency room visits and outpatient visits among the incident digoxin-specific CM elderly users. Almost all these outcomes, however, were not statistically significantly different, except for the use of potassium-sparing medications and NSAIDs (P ¼ 0.016 and o0.001, respectively) ( Table 4 ).
Discussion
In this study, we found that only 3% of elderly NHI beneficiaries were prescribed with digoxin in 2006. Also, they were less likely to be prescribed with concentrated CMs with digoxin (0.43%) and only half of them were newly prescribed with concentrated CM (0.22%) in 2006. Although digoxin was prescribed for 190 days on average to those NHI elderly beneficiaries in 2006, the concentrated CMs were somewhat less commonly prescribed concomitantly (i.e., average duration was approximately 17 days). The following factors were statistically significantly associated with the incremental incidence of concurrent digoxin-CM use and the incremental occurrence of digoxin-specific CM interactions: previous diagnosis of heart diseases or BPH, outpatient clinic visits per month ranging from two to five, or more distinct medications prescribed in 2006. In contrast, those elderly NHI beneficiaries enrolled in the south region were less likely to encounter incident digoxin-CM concurrent use and incident digoxin-specific CM interactions. More than 96% of all incident digoxin-CM elderly users had encountered the evidence-approved digoxin-specific CM interactions. Although their 3-month follow-up medical outcomes after the initial occurrence were evaluated, no statistically significant findings were found.
In this study, we found that elderly patients were relatively less likely to be prescribed with this narrow therapeutic index medication, digoxin, in Taiwan, whereas 17% of older adults were initially prescribed with digoxin in the United States [30] . Another study also showed that 38% of HF NHI beneficiaries of all age were prescribed with digoxin and 26% were newly prescribed in Taiwan [31] . Although 7% to 21% of the patients with cardiovascular symptoms took herbal medicine in the United States and other countries [32, 33] , there was a relatively low prevalence and incidence of digoxin-CM use among the elderly in this study (0.43% and 0.22%, respectively). Such rates were comparatively
lower than the findings obtained from a nationwide survey in Taiwan in 2001 (i.e., 4.3% of all survey participants used both NHIcovered all kinds of Western medication and TCM) [34] and that of our previous population-based cohort study using 1 million NHIRD data for all ages of digoxin users (10.7% and 5.4%, respectively) in 2005 [14] . In addition, the duration of concurrent use in this study was approximately 2 days less than that obtained from all age incident digoxin-CM users (19.3 Ϯ 29.9 days) in 2005 [14] . One study showed that 28% of all NHI beneficiaries had used NHI-covered TCM services in 2001, 62.5% had used NHI-covered TCM services at least once from 1996 to 2001, and 86% had ever been prescribed with concentrated CMs in Taiwan [35] . In this sense, our study showed that those Western medicine physicians who prescribed digoxin for the elderly in Taiwan were more conservative than those in other countries, than for all aged patients with HF, and for all age digoxin users in Taiwan. Also, those Chinese medicine physicians more stringently prescribed concentrated CMs for elderly patients with Examining the outcomes associated with new occurrence of digoxin-specific CM interactions after three month follow-up since initial concurrent use among incident digoxin-specific CM users and matched digoxin-only elderly users
Elderly encountered incident digoxin-specific CM interactions and had health service records after three month follow-up since initial concurrent use were identified for further assessments N=351
Mached digoxin-only elderly users who still has health service records after three month follow-up since initial concurrent use were identified for further assessments N=341
Exploring the contributing factors associated with incident digoxin-CM use and incident of digoxin-specific CM interactions in 2006 among the elderly NHI beneficiaries Fig. 1 -Study population. CM, Chinese medication; LHID, longitudinal health insurance database; NHI, national health insurance. *For each incident digoxin-CM elderly user, we randomly selected a digoxin user from the propensity score derived from the combination of the following variables: the month of the index date, the same duration of digoxin use, age, with or without catastrophic certification, outpatient clinic visits per year, number of prescribed distinct medications, total medical expenditure. † There were 385 incident digoxin-CM elderly users prescribed with specific CMs, which were proven to have interactions with digoxin (i.e., incidence of digoxin-specific CM interaction among elderly ¼ 0.21%) so that another 385 elderly who were prescribed with digoxin only were matched accordingly on the propensity score. Note. We used chi-square tests and t test to compare differences between incident digoxin-CM elderly users and digoxin-only elderly users for nominal scale and continuous variables. CM, Chinese medication; CHM, Chinese herbal medication; NHI, National Health Insurance; TWD, New Taiwan dollar. * There were statistically significant differences between the elderly encountered incident digoxin-CHM use and the corresponding digoxinonly elderly users. † Ascertained during the 6-mo period before the date of first CM prescription. ‡ There were statistically significant differences between elderly encountered incident digoxin-specific CM interactions and the corresponding digoxin-only elderly users. 
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digoxin for some unknown reasons. Nevertheless, it is unknown whether this phenomenon occurred because of concern over potential digoxin toxicities after the announcement of Beer's criteria in 2003 [36] or because of other reasons. Furthermore, we found that those elderly with heart diseases and BPH were 2.15 and 2.02 times, respectively, likely to be newly prescribed with concentrated CMs when they had a prescription of digoxin at the same time compared with those who did not have these diseases. This was also true when controlled for other factors. In contrast, there were no statistically significant differences in the extent of ORs among those who had chronic kidney diseases, myocardium infarction, ventricular arrhythmias, and HF during the 6-month period before the index date. Using propensity scores to reduce the likelihood of selection bias in this study, it implies that those elderly on digoxin and with heart diseases and BPH were more likely to be newly prescribed with concentrated CMs, whereas such occurrence existed beyond that which is possible due to chance. In fact, our findings were different from a previous study focusing on all age adults who were ever prescribed with seven high-risk Western mediations (aspirin, clopidogrel, dipyridamole, ticlopidine, heparin, warfarin, and digoxin) in Taiwan [14] . A systematic review showed that Chinese herbal medicine is more impressive with regard to the improvement in quality of life, reduction of prostate volume, and the occurrence of adverse events compared with Western medications, although the evidence is not robust to support the efficacy of Chinese herbal medicine for BPH [37] . Although the number of patients with prostate cancers using covered CMs increased from 1996 to 2008 (i.e., 72.8% to 78.8% of all TCM therapies) in Taiwan [38] , it is understandable that the usage of CMs with digoxin among those elderly with BPH in Taiwan might increase for the BPH, benign prostatic hyperplasia; CI, confidence interval; CKD, chronic kidney disease; CM, Chinese medication; CHM, Chinese herbal medication; NHI, National Health Insurance; OR, odds ratio. * There were statistically significant differences between the occurrence of digoxin-CHM interactions, where 95% CI not included 1. † There were statistically significant differences between the elderly encountered incident digoxin-CHM use and the corresponding digoxinonly elderly users. ‡ There were statistically significant differences between the occurrence of digoxin-specific CHM interactions, where 95% CI not included 1. ( 2 0 1 4 ) 2 1 1 -2 2 1 aforementioned reasons. We focused only, however, on 1 year of NHI utilization in Taiwan in 2006. Therefore, further exploration about the utilization of CMs with Western medications for prostate-related diseases across time after 2006 or for the most updated databases might be necessary.
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In Taiwan, the implementation of NHI as a single-payer, social insurance plan has provided almost all citizens with modest cost sharing. At present, the coverage of the population is as high as 99%, so the Bureau of NHI has provided the NHIRD for corresponding research on issues related to cost quality of health services, medical practice patterns, accessibility to health care programs, and treatment outcomes at the national or local level. The Bureau of NHI has had contracts with 97% of registered hospitals, which provide Western and/or Chinese medicine services, since 1996 to ensure sufficient access in Taiwan. Approximately 92% of all hospitals that provided Chinese medicine services were contracted by the Bureau of NHI to offer TCM medical care. In our study, we found that those elderly NHI beneficiaries enrolled in the south region were less likely to encounter incident digoxin-CM concurrent use and incident digoxin-specific CM interactions, while there was no difference among the other regions. Such a finding is inconsistent with our previous study, as well as with the results of other studies [14, 25, 35, 39, 40] . In contrast, all the other studies showed that NHI beneficiaries enrolled in the central region were more likely to be prescribed concentrated CMs with Western medications, including digoxin, while no differences were identified among the other regions in this study. More studies might be necessary to explore the rationales beyond for the regional differences in NHIcovered CM utilization.
It is reasonable to hypothesize that those elderly NHI beneficiaries who ever visited Western and Chinese medicine clinics in the same period of time would require a greater number of outpatient visits and would be prescribed with more distinct medications, including Western and Chinese medications. Consequently, these two factors were statistically associated with the Table 4 -Effect of concurrent use of digoxin with CHM after 3-mo follow-up since initial concurrent use.
Effect/outcomes after 3-mo follow-up n (%) P 
incremental incidence of digoxin-CM concurrent use and digoxin-specific CM interactions. Those who had made two to five outpatient clinic visits per month, however, were more likely to encounter new digoxin-CM concurrent use and digoxinspecific CM interactions; this was different from our previous study focusing on all age NHI adult beneficiaries for high-risk Western medications (including anticoagulants and digoxin) in 2005 [14] . We presumed that the elderly population might contribute to such difference. Importantly, this study retrieved the 3-month follow-up information about relevant clinical and economic consequences after the new occurrence of digoxin-specific CM interactions among the NHI elderly beneficiaries, which accounted for almost all incident digoxin-CM elderly users. Although those who encountered digoxin intoxications might also experience ventricular arrhythmia, atrioventricular block, bradycardia, acute renal failure, or hypopotassemia, and may require follow-up digoxin level evaluations, we were also concerned about the other relevant outcomes, including medical care expenditure, abnormal electrolyte disorders, and concomitant prescribed medications. All these outcomes might be associated with digoxin toxicities, other than the all-cause hospitalizations. Finally, we did not find any statistically significant difference in these potentially relevant outcomes, the factors associated with digoxin toxicity, or the concomitant medications.
The incident digoxin-specific CM elderly users, however, were prescribed with more potassium-sparing diuretics and NSAIDs than their counterpart digoxin-only elderly users. It is unclear whether the potassium-sparing diuretics were prescribed to manage the problem of hypopotassemia, to prevent the occurrence of digoxin toxicities, or for other reasons. Although 0.39% of new digoxin users were diagnosed with digoxin intoxication (ICD- [31] , only 1 elderly individual in each group was documented to have encountered digoxin intoxication during the 3-month period after the index dates of the incident occurrence of digoxin-specific CM interactions in this study. In other words, the incidence of documented digoxin intoxication was relatively low (i.e., 0.03%) among all elderly prescribed with digoxin in 2006 in this study. Although the nested case-control studies using open cohorts were performed to explore the risks of exposing interactions between digoxin and diuretics, as well as other medications [31, 41] , further studies using different study designs (e.g., nested case-control study, case cross-over study) to involve more subjects and compare subjects by themselves might be necessary to confirm our findings.
A previous study demonstrated that higher serum digoxin concentrations were statistically associated with incremental mortality for those patients with HF [42] . The use of digoxin was associated with a significant increase in all-cause mortality in patients with atrial fibrillation [43] . Although HF and atrial fibrillation are common diseases among the elderly, digoxin utilization is indeed decreased in Taiwan compared with HFrelated findings obtained from Wang et al.'s study between 2001 and 2004 [31] . It is presumed that one reason for this might be the inferior effectiveness of treatment compared with betaadrenergic inhibitors, angiotensin-converting enzyme inhibitors, and angiotensin II receptor blockers for HF [9] . Nevertheless, several studies have recommended not overlooking digoxin toxicities, especially for those who are older, female patients, with low lean body weight, with renal insufficiency, and with concomitant medication use [9, 14, 42, 43] . All these studies suggest that checking digoxin concentration is necessary to evaluate the risk and benefit for those digoxin users for any condition. Only approximately 5% of all elderly individuals with digoxin prescriptions, however, were ordered to check their digoxin levels during the 3-month period after the date of incident digoxinspecific CM interactions and the corresponding digoxin-only use in this study. Further studies might be necessary to examine the rationale and the actual risks and benefits of this phenomenon.
Although 32% of all-cause hospitalizations were found in the following 3 months after exposure to digoxin-specific CM interactions, there were relatively rare occurrences of digoxin intoxication, arrhythmia, bradycardia, acute renal failure, or hypopotassemia in this study. These might be due to underreporting or underdocumenting the relevant signs, symptoms, precipitant factors, and associated concomitant medications in the health care settings and/or the fact that no actual harmful effect occurred for some reasons. With the relatively less common use of digoxin, incident digoxin-CM use, and incident digoxinspecific CM interactions, the rare occurrence of clinical and economic consequences in any aspect might encounter a type II error because the sample size is not big enough for the assessment of outcomes. Further studies using open cohort across several study years to recruit more subjects might be able to overcome this pitfall, in particular if digoxin use and digoxin-CM concurrent use were not as rare as our findings suggest.
In addition, several other limitations in our study need to be addressed. First, there is limited information describing actual medication use patterns (NHI-covered medications only), disease status (up to three diagnoses were documented in outpatient data sets and up to five diagnoses in inpatient data sets), and health service utilization patterns (only NHI-covered and copayment) using the NHIRD, which are derived from the LHID administrative claimed data sets. Unfortunately, the corresponding indications of CMs and digoxin were unknown using the NHIRD. In fact, the relevant ICD-9 codes, in terms of indications for all prescribed Western medicine, are required in each CM prescription, although TCM physicians usually make their decisions of CM prescription on the basis of complex TCM theories (e.g., yin/yang, five elements, Jing, blood, qi, Jin Ye). Thus, the listed ICD-9 codes associated with CMs and digoxin were ascertained during the 6-month period before the dates of first CM prescription, in terms of index dates. Focusing on 1 year of NHI utilization in 2006 in Taiwan, the definition of 1-day exposure might cause the overestimation of its incidence and prevalence of concurrent use. Although only 6% of the adults had ever used noncovered TCM therapies [44] and the majority of all NHI beneficiaries using TCM therapies had ever been prescribed with concentrated CMs in Taiwan [35] , this study explored the actual concurrent use patterns of digoxin with concentrated CMs among the elderly. Second, there is more than one active chemical compound in one single CM, which might have various concentrations of corresponding chemical compounds due to coming from different locations and seasons. There are no official documents listing all active chemical compounds in the concentrated CM products yet, let alone having published information listing the recommended dose/concentration, duration, and frequency of any particular chemical compound. Thus, it is unknown what chemical compounds in the concentrated CMs interact with digoxin. Instead, we focused on those prespecified CMs that were documented in various levels of the literature. Although several of these CMs are either a component of Asian food or an ingredient in Asian cuisine, unfortunately, the NHIRD included only those covered CMs. Information about the diets, nutrition, or foods with these CMs in the NHIRD is available.
Third, the extent of concurrent use in this study was different from that in other studies due to the different data resources, study designs, and focused populations, as well as the definitions of Western medications and CMs. For instance, by using the NHIRD we cannot know for what indications these concentrated CMs were prescribed. The review of medical charts using inhouse databases across different hospital settings might be able ( 2 0 1 4 ) 2 1 1 -2 2 1 to provide such indication-related information. Fourth, the specified propensity scores were used to 1:1 match the counterpart digoxin-only elderly users with incident digoxin-CM elderly users and incident digoxin-specific CM users. There were still some different characteristics between incident digoxin-CM elderly users/incident digoxin-specific CM elderly users and the corresponding digoxin-only elderly users. Thus, we did not perform conditional logistic regression, as other studies did [11, 32] , to examine the factors associated with new concurrent use and interactions of digoxin and CMs. Instead, we conducted traditional univariate and multivariate logistic regression analyses, which assumed that individuals were independent from each other. Furthermore, although our findings could be an example to other countries practicing Chinese medicine or CAMs commonly, future cross-nation studies in Asia or worldwide might be needed to verify the findings and enhance their generalization.
In conclusion, there were relatively rare incidents of digoxin prescription, digoxin-CM use, and the occurrence of new digoxinspecific CM interactions among the elderly in Taiwan. Although those who used more outpatient services and medications might increase the exposure of incident digoxin-CM use and incident digoxin-specific CM interactions among the elderly, more attention should be paid to those elderly with specific diseases (heart disease and BPH) and checking their digoxin concentration more aggressively to follow-up the risks and benefits. We recognize this study as an initiative to explore the elderly concurrent use of CMs with digoxin, and demonstrated that no significant harm occurred. Overall, these findings are substantial and informative to support that Taiwanese physicians practicing either Western medicine or Chinese medicine are very responsible in prescribing medications cautiously for the elderly. It is presumed that they intend to mitigate problems associated with a system that has patients using multiple prescribers and visiting multiple hospital settings, possibly with concerns about medication toxicities that the patient may experience.
